Working... Menu

Expanded Access to ABBV-8E12

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03744546
Expanded Access Status : Available
First Posted : November 16, 2018
Last Update Posted : April 16, 2019
Information provided by (Responsible Party):

Tracking Information
First Submitted Date November 14, 2018
First Posted Date November 16, 2018
Last Update Posted Date April 16, 2019
Descriptive Information
Brief Title Expanded Access to ABBV-8E12
Official Title Expanded Access to ABBV-8E12
Brief Summary This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-8E12 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
  • Primary Tauopathy
  • Primary Supranuclear Palsy (PSP)
  • Corticobasal Degeneration Syndrome (CBD)
Intervention Drug: ABBV-8E12
Solution for infusion
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Available
Eligibility Criteria Not Provided
Sex/Gender Not Provided
Ages 40 Years and older   (Adult, Older Adult)
Contact: ABBVIE CALL CENTER 847.283.8955
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT03744546
Other Study ID Numbers C19-364
C19-921 ( Other Grant/Funding Number: AbbVie )
Responsible Party AbbVie
Study Sponsor AbbVie
Collaborators Not Provided
Study Director: AbbVie Inc. AbbVie
PRS Account AbbVie
Verification Date April 2019